Physician profile
Gary Spektor
NPI 1043275092
$3,518.97
in general payments reported to CMS, 2019-2025
23 companies · $87.64 in 2025
The $87.64 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $680 · 2020: $1,005 · 2021: $998 · 2022: $190 · 2023: $428 · 2024: $131 · 2025: $87.64.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $647.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $646.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $601.78 | 2019-2024 | |
| Amarin Pharma, INC. | $577.77 | 2019-2023 | |
| Pfizer INC. | $330.88 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $256.21 | 2019-2023 | Xarelto |
| Esperion Therapeutics, INC. | $254.67 | 2020-2024 | Nexletol |
| Kowa Pharmaceuticals America, INC. | $230.64 | 2019-2021 | |
| Irhythm Technologies, INC. | $220.71 | 2020-2024 | Zio Xt Patch, Zio Monitor, Zio At Patch |
| E.R. Squibb & Sons, L.L.C. | $200.26 | 2019-2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $123.42 | 2020-2023 | Lifevest |
| Astrazeneca Pharmaceuticals Lp | $113.68 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $93.62 | 2020-2021 | |
| Bardy Diagnostics, INC. | $76.84 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $70.40 | 2021-2025 | Verquvo |
| Octapharma USA, INC. | $64.94 | 2025 | Balfaxar, Fibryga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $63.57 | 2019-2023 | Jardiance |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shockwave Medical, INC | $57.83 | 2023 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Kiniksa Pharmaceuticals, Ltd. | $34.69 | 2023 | Arcalyst |
| Boston Scientific Corporation | $34.61 | 2019 | |
| Abiomed | $31.03 | 2019 | |
| Arbor Pharmaceuticals, INC. | $28.31 | 2019 | |
| Medtronic, INC. | $19.92 | 2024 | Closurefast |
| Terumo Medical Corporation | $18.14 | 2019 | |
| Abbott Laboratories | $15.05 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Spektor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.